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Fibrin formation represents a major defense and repair mecha-
nism, which ensures the integrity of the vascular system (1–3). 
Together with platelets, which adhere and aggregate at sites of ves-
sel injury, fibrin formation is mandatory for stable sealing of the 
ruptured vessel wall and for prevention of life-threatening blood 
loss. Apart from its immediate actions necessary to arrest bleed-
ing, fibrin also regulates the subsequent steps of wound healing. 
To accomplish its multiple functions only in cases of vascular wall 
damage, blood coagulation is functionally inactive in the intact 
vasculature but is rapidly triggered when the barrier function of 
the endothelium is perturbed. The initiation process of fibrin for-
mation is known to crucially demand tissue factor (TF), a type I 
membrane protein predominantly resident in the cell membrane. 
TF, which is expressed by cells of the vascular wall, blood cells, 
and cell-derived microvesicles (or microparticles; ref. 4), promotes 
fibrin formation by increasing the proteolytic activity of the coag-
ulation factor VIIa by several orders of magnitude. This requires 
the interaction of factor VIIa with the membrane-proximal region 
of the extracellular domain of TF.
Aberrant activation of blood coagulation is a major determinant 
of thrombotic occlusions of arteries and veins (4, 5). Among other 
complications, this may lead to arterial thrombosis resulting in 
myocardial infarction and stroke, which constitute the major 
causes of morbidity and mortality in most industrialized coun-
tries. While hemostasis and thrombosis are mechanistically dif-
ferent processes, TF is likely to contribute also to both arterial and 
venous thrombosis. Indeed, TF present in atherosclerotic arteries 
is supposed to be a major trigger for intravascular thrombus for-
mation after rupture of atherosclerotic plaques (4, 5).
The coagulation start is thought to be maintained in a silent 
state by a condition that has been designated as TF encryption 
(6, 7), in which the protein is correctly inserted in the plasma 
membrane, but is functionally inactive. TF encryption has been 
documented for a vast number of cell types and for microparticles 
(8, 9). Several conditions modulate TF activity, including the mem-
brane domain association of TF (10) and the phosphatidylserine 
transmigration to the outer leaflet of the plasma membrane (11). 
TF activity is also modulated by the redox state of its membrane 
proximal cysteine pair (Cys186/Cys209) (12), and oxidation of this 
cysteine pair increases the procoagulant function of TF. However, 
it is unclear which of these mechanisms is of relevance for TF 
activation during thrombus formation. Indeed, the nature of the 
stimuli that initiate fibrin generation after vessel injury in vivo and 
the way in which these stimuli convert TF from the encrypted to a 
functionally active state have remained largely undefined.
Results
Activation of coagulation by microparticle TF requires disulfide isomerases 
in vivo and in vitro. To study the mechanisms implicated in TF acti-
vation, we used extracellular membrane vesicles (microparticles), 
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Figure 1
TF-dependent luminal fibrin generation in vivo is controlled by PDI. (A) Platelet-secreted disulfide isomerases activate microparticle TF. Left: 
Monocyte microparticles (MP; 106) were incubated with collagen-activated platelets (P; 5 × 107). Microparticles (α-TF/MP) or activated platelets 
(α-TF/P) were selectively preincubated with anti-TF antibody (10 μg/ml). Unbound antibody was removed by centrifugation. *P < 0.05. Right: 
Microparticles were incubated with activated platelets for 10 minutes, then bacitracin, anti-PDI antibody, or control antibody were added to 
bypass inhibition of platelet stimulation. TF activity was determined by 2-stage assay. *P < 0.05 versus MP/P. Means ± SD; n = 5. (B) Platelet-
released PDI stimulates TF activity. Supernatants (P-SN) recovered from activated platelets (109) were incubated with microparticles (106) plus 
anti-PDI antibody or control antibody (15 minutes). The procoagulant activity (2-stage assay) was suppressed by anti-TF antibody. *P < 0.05 
versus control antibody. n = 4. (C) Microparticles accelerate fibrin production in mice. Microparticles (107; in 250 μl) were infused into WT mice 
after carotid ligation injury. MP (α-TF), microparticles precoated with α-TF. Top: Fibrin (pseudocolored) was visualized by intravital videofluores-
cence microscopy using an Alexa Fluor 488–labeled anti-fibrin antibody. Measurements were performed before (pre injury) or 5 and 30 minutes 
after injury. Scale bar: 50 μm. Bottom: Quantitative analyses of the data. Means from 2 experiments, 30-minute values. (D) PDI contributes to 
microparticle-driven initiation of coagulation. Anti-PDI antibody (also recognizing murine PDI, 800 μg/animal) or control IgG were infused into WT 
mice (15 minutes after injury), then microparticles (107) were added (arrows). Fibrin formation at the injury site was monitored. *P < 0.05 versus 
isotype IgG. n = 4–6. (E) Microparticle recruitment is unchanged by PDI suppression. Anti-PDI antibody was infused 15 minutes after carotid 
injury. Then DCF-tagged microparticles were infused. Labeled microparticles at lesion site were measured by intravital microscopy. n = 3–4.
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which are major TF carriers in blood (9) and in atherosclerotic 
plaques (13). The TF activity of isolated monocyte-derived mic-
roparticles alone was low, indicating that microparticle TF was 
functionally mostly inactive (encrypted) (Figure 1A). Micropar-
ticles coadhere with platelets at vascular lesions (14, 15), and this 
interaction could be involved in the activation of microparticle 
TF (16). Indeed, the procoagulant activity of microparticle TF 
was amplified substantially by activated platelets (Figure 1A). 
Activated platelets are known to release disulfide isomerases (17), 
which regulate thiol modifications. To test the potential partici-
pation of these enzymes in the activation of microparticle TF, we 
used bacitracin, a broad inhibitor of the oxidoreductase protein 
disulfide isomerase (PDI) and other disulfide isomerases (17). 
Bacitracin partially prevented activation of microparticle TF by 
activated platelets (Figure 1A). In addition, selective suppression 
of PDI by an anti-PDI antibody attenuated TF activation induced 
by activated platelets (Figure 1A). The control antibody was with-
out effect. Inhibition of PDI also suppressed stimulation of mic-
roparticle TF when intact platelets were substituted by platelet 
releasates (Figure 1B). Platelet-released PDI thus contributes to 
activation of microparticle TF independent of the presence of the 
activated platelets themselves.
To address the role of PDI in the microparticle-induced initia-
tion of coagulation in vivo, vascular injury was induced by liga-
tion of the carotid artery (18). Using a labeled anti-fibrin antibody, 
fibrin formation at the injury site was visualized in real time by 
high-speed intravital fluorescence microscopy (Figure 1C). Experi-
ments with a labeled control antibody verified the specificity of the 
signal. Infusion of microparticles into the jugular vein of WT mice 
increased fibrin generation on the thrombus surface (Figure 1C). 
Microparticle TF was confirmed as trigger of coagulation, since 
infusion of microparticles coated with anti-TF antibody largely 
failed to increase the fibrin formation (Figure 1C), extending pre-
vious work (19). Next, to inhibit PDI in vivo, the anti-PDI antibody 
(or control antibody) was infused into the murine blood circula-
tion before infusion of microparticles. In the presence of control 
antibody, microparticles increased fibrin formation (Figure 1D), 
in agreement with the results of Figure 1C. In contrast, inhibition 
of PDI suppressed the coagulation activation in the presence of 
infused microparticles. This was not due to an effect of PDI inhibi-
tion on microparticle attachment per se (Figure 1E).
Then we visualized the localization of PDI in the surroundings 
of the vessel injury site. Using immunohistochemistry, we detected 
intraluminal accumulation of PDI at the site of the vessel lesion, in 
particular on the surface of thrombus-associated platelets (Figure 
2A). Furthermore, PDI was located in the vessel wall (Figure 2A), 
in particular in association with vascular smooth muscle cells, as 
indicated by costaining with smooth muscle actin (not shown). In 
the unperturbed vasculature, the localization of PDI was restrict-
ed to the vessel wall (Figure 2A). The labeled control antibodies 
yielded negligible staining, mostly of the vessel adventitia. Lumi-
nal exposure of PDI at the injury site was confirmed by intravital 
microscopy (Figure 2B). Again, no intraluminal localization of 
PDI was detected in the intact vessel. The PDI exposure in injured 
vessels could originate from activated platelets and, additionally, 
from the ER of disrupted cells of the vessel wall. The latter origin 
is a likely possibility, since PDI is present in the millimolar range 
within the ER (20, 21). Moreover, experiments with mechanically 
wounded CHO cells (cell scraping) in vitro indicate that cell injury 
induces the release of PDI together with other ER lumenal pro-
teins (e.g., GRP94 and GRP78; data not shown). To distinguish 
between platelet- and vessel wall–derived PDI, we induced massive 
thrombocytopenia by targeting platelet GPIbα with an antibody 
mixture that suppresses platelet counts by more than 95% (22). In 
Figure 2
Specific exposure of PDI in the wounded area of the vessel wall. (A) Vessel injury causes appear-
ance of intraluminal PDI in association with platelets. Fifteen minutes after ligation, vessel seg-
ments containing the injured area were excised and subjected to immunohistochemistry using an 
Alexa Fluor 594–labeled anti-PDI antibody. Platelets were stained with Alexa Fluor 488–labeled 
anti-CD41 antibody, and nuclei were visualized with DAPI. Arrows indicate PDI located in the 
vessel wall. Arrowheads show platelet-associated PDI. In parallel, the vessel segments were 
exposed to labeled isotype control antibodies. (B) PDI exposure at vessel injury site. Alexa Fluor 
488–labeled anti-PDI antibody (or Alexa Fluor 488–labeled control antibody) was infused into WT 
and thrombocytopenic (platelet-depleted) mice (22) before and 15 and 25 minutes after vessel 
injury. The distribution of the labels at the injury location was visualized by intravital microscopy. 
Values obtained with anti-PDI antibody were normalized to values obtained with control antibody. 
#P < 0.05 compared with pre-injury; *P < 0.05 compared with control. n = 6.
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thrombocytopenic mice, we observed PDI exposure at the injury 
site by intravital microscopy 15 and 25 minutes after vessel injury 
(Figure 2B). After 30 minutes, release of PDI was decreased in these 
mice compared with control mice, suggesting that the luminal 
exposure of PDI in WT mice at this time point is mostly derived 
from platelets. Together this indicates that the PDI exposed at the 
site of vessel injury not only originates from activated platelets but 
also from the disrupted vessel wall cells. In summary, PDI selec-
tively exposed at sites of vascular lesions is required for TF-trig-
gered fibrin generation.
PDI triggers TF-dependent blood coagulation in mice. We then deter-
mined whether PDI is involved in fibrin formation in the absence 
of exogenously applied microparticles. We monitored fibrin gen-
eration in mice expressing human TF (hTF mice; ref. 23) at levels 
comparable to its murine counterpart in WT mice. In hTF animals 
there was extensive fibrin production at the injury site (ligation 
injury; Figure 3A). In contrast, fibrin formation was minimal in 
mice with low hTF (24). Hence hTF mice enabled analysis of hTF-
driven fibrin generation in vivo. To suppress the PDI activity in 
the vessel wound, the anti-PDI antibody was infused into the hTF 
animals prior to induction of vessel injury. Inhibition of PDI sub-
stantially reduced fibrin formation at the injury site (Figure 3A), 
which was accompanied by a decrease in the total area occupied 
by fibrin. Moreover, experiments performed in WT mice showed 
that blockade of PDI substantially attenuates fibrin formation fol-
lowing endothelial disruption (Figure 3B). Nonetheless, prelimi-
nary experiments indicate that the tail bleeding times in WT mice 
treated with anti-PDI antibody are not significantly prolonged 
compared with treatment with control IgG (1428 ± 61 s [anti-PDI] 
vs. 996 ± 208 s [control IgG]; mean ± SEM, n = 5 animals per treat-
ment). To test whether the influence of the antibody was due to 
a strong inhibitory effect on platelet adhesion at the injury site, 
Figure 3
PDI contributes to trigger TF-dependent fibrin forma-
tion under conditions of suppressed platelet adhesion. 
(A) TF-dependent initiation of coagulation in living ani-
mals. Left: Fibrin formation was assessed 15 minutes 
after carotid artery ligation by intravital microscopy 
in hTF mice and low-hTF mice. Scale bar: 50 μm. 
Right: Quantitation of fibrin formation at site of ves-
sel injury. Effect of anti-PDI antibody (or control anti-
body; infused before implementing the vessel injury) 
on fibrin formation in hTF animals. *P < 0.05 versus 
isotype control. n = 4. (B) PDI contributes to fibrin for-
mation in mice with normal platelet counts. Fibrin gen-
eration was assessed before or after vascular injury 
(ligation) in WT (SV129S1) mice pretreated with the 
indicated antibodies prior to induction of vessel injury. 
*P < 0.05 versus isotype control. n = 4. (C) GPVI 
inhibition decreases platelet adhesion. Firm platelet 
adhesion of rhodamine-labeled platelets to the injured 
artery (ligation) was visualized 15 minutes after injury 
in the presence of control antibody or neutralizing 
anti-GPVI antibody (hTF mice). *P < 0.05. n = 8. 
(D) PDI regulates fibrin formation under conditions 
of decreased platelet adhesion. Platelet adhesion 
was inhibited by infusion of anti-GPVI antibody (hTF 
mice). Thrombocytopenia was induced by injection 
of anti-GPIbα antibody (platelet-depleted WT mice). 
Both groups were then treated intravenously with 
anti-PDI antibody or control antibody, vessels were 
injured, and fibrin formation was determined after 15 
minutes. *P < 0.05 versus isotype control. n = 7–10. 
(E) PDI increases fibrin formation after wire-induced 
vessel injury. Fibrin formation after wire-induced injury 
of the murine carotid artery was assessed by western 
blotting in the presence of α-PDI or control IgG. The 
anti-fibrin antibody specifically detects fibrin but not 
fibrinogen. Thrombi were excised 15 minutes after 
vascular injury.
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we suppressed platelet adhesion by blocking the platelet collagen 
receptor GPVI (Figure 3C). This did not influence blood platelet 
counts (644 ± 80 × 103/μl before injection and 584 ± 46 × 103/μl 
after injection of anti-GPVI antibody; mean ± SEM, n = 4–6). In 
hTF mice with decreased platelet adhesion, fibrin formation at the 
injury site was lowered (Figure 3D versus Figure 3A). This con-
firms that platelet adhesion/activation contributes to fibrin gen-
eration following vascular injury. However, also under conditions 
of decreased platelet adherence, fibrin formation was decreased 
following infusion of anti-PDI antibody (Figure 3D). Moreover, in 
thrombocytopenic WT mice, fibrin formation at the vessel injury 
site was diminished by PDI inhibition (Figure 3D). Together our 
findings indicate that PDI inhibition lowers fibrin formation both 
in the presence of platelet adhesion and under conditions of sup-
pressed platelet adherence. This suggests that PDI released from 
disrupted vessel wall cells (Figure 2B) also contributes to initiation 
of fibrin formation. To determine whether PDI-driven initiation of 
coagulation is also relevant in another model of thrombus forma-
tion, the endothelium of the carotid artery was denudated by a 
wire device (18). Subsequently, fibrin generation was determined 
by immunoblotting of isolated thrombi in WT mice. Also fibrin 
formation in response to wire injury was substantially decreased 
by suppression of PDI (Figure 3E).
To evaluate whether TF disulfide exchange contributes to PDI-
mediated fibrin formation in the intact animal, microparticles 
were pretreated with the free thiol–selective reagent 5,5′-dithio-
bis(2-nitrobenzoic acid) (DTNB) before infusion of microparticles 
into the murine blood. This prevented the acceleration of fibrin 
production by microparticle-derived TF in the ligation model (Fig-
ure 4A). Next, the anti-PDI antibody was infused into the animals 
following injection of DTNB-pretreated microparticles to inhibit 
the interaction of PDI with microparticle TF. As a result, fibrin for-
mation at the lesion site was no longer diminished by the anti-PDI 
antibody (Figure 4B), in contrast to its inhibitory effect after infu-
sion of untreated microparticles under similar conditions (data 
not shown). This indicates that the anti-PDI antibody inhibits the 
PDI-mediated thiol-disulfide exchange and decreases the activa-
tion of TF in vivo. In a complementary approach, native PDI was 
added to the circulation of the hTF animals prior to induction 
of vessel injury. This augmented the focal fibrin generation (Fig-
ure 4C), indicating that exogenous enzyme can enhance the effect 
of endogenous PDI. Overall, the results from different models of 
thrombogenesis suggest that fibrin generation at the lesion site is 
supported by PDI-mediated disulfide exchange of TF.
PDI induces disulfide bond formation in TF. To evaluate how activated 
platelets and PDI might activate TF, we tested their effects on the 
sulfhydryl status of TF. The extracellular TF domain (soluble TF 
[sTF]; lacking the transmembrane and cytoplasmic domains) was 
labeled with 3-(N-maleimidylpropionyl)-biocytin (MPB), which 
selectively reacts with free thiols (25). In folded sTF (see Meth-
ods), only the C186/C209 pair is accessible to solvents (26, 27). 
After exposure of sTF to supernatants from activated platelets, 
the number of free thiols of sTF was decreased (Figure 5A), con-
sistent with disulfide formation. Cell lysate, another TF activator, 
also diminished TF free thiols (data not shown). Furthermore, PDI 
decreased the number of free thiols in sTF (Figure 5A). In con-
trast, the reductase thioredoxin (TRX) slightly increased the TF 
free thiols. Western blots performed in parallel excluded that the 
different experimental conditions and the MPB labeling affected 
recognition of sTF by the anti-TF antibody (Figure 5A). The densi-
ties of the bands obtained by MPB labeling of sTF plus subsequent 
pulldown with streptavidin agarose (indicated as MPB-IB in Fig-
ure 5A) cannot be directly compared with those obtained by direct 
western blotting of MPB-labeled sTF and hence cannot be used 
for quantitative determination of the amount of TF containing 
free thiols because of the different procedures employed (see also 
legend to Figure 5A). We next assessed the extracellular free thiols 
in full-length TF expressed in human monocytes, using MPB con-
centrations that were not associated with cell internalization of 
the probe. Free thiol groups were detected in cell surface TF. These 
were diminished by PDI (Figure 5B).
Constitutive glutathionylation of TF contributes to maintaining a low TF 
activity. To further specify thiol modifications of TF, we assessed 
whether cell TF was glutathionylated, which represents a major 
thiol modification of several proteins containing redox-active cys-
teines (28). Glutathionylated proteins in cell lysates of monocytes 
and glutathionylated cell surface proteins in intact cells were 
Figure 4
TF disulfide exchange supports fibrin production in vivo. (A) Prevention 
of TF disulfide switching inhibits fibrin generation. Monocyte micropar-
ticles were preincubated for 30 minutes ex vivo with DTNB (1 mM; 
DTNB-MP) or vehicle (control-MP). Then they were infused into the 
murine blood. Fibrin generation at the lesion site (ligation injury) was 
determined 15 minutes after infusion of microparticles. *P < 0.05. n = 4. 
(B) PDI inhibition requires functioning disulfide exchange in vivo. The 
anti-PDI antibody (or control antibody) was infused following incorpora-
tion of DTNB-pretreated microparticles into the murine blood circula-
tion. Fibrin generation at the lesion site (ligation injury) was determined 
15 minutes after infusion of microparticles. n = 4. (C) TF-driven fibrin 
formation is enhanced by PDI. PDI (200 μg/animal) was included in the 
blood circulation of hTF mice, and fibrin generation was registered 10 
minutes after vessel injury at the lesion site (ligation injury). Scale bar: 
50 μm. *P < 0.05. n = 6.
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immunoprecipitated with an anti-glutathione antibody. To 
assess whether TF was among the glutathionylated proteins, this 
was followed by TF detection on western blots using an anti-TF 
antibody. The results show that full-length TF in cell lysates (Fig-
ure 6A) and on the cell surface (data not shown) contains mixed 
disulfides with glutathione. In parallel experiments we found that 
exposure of sTF labeled with biotin-glutathione (Figure 7A) to cell 
lysates from CHO cells decreased TF glutathionylation (data not 
shown), suggesting that the amount of glutathione conjugated to 
TF might be underestimated by the IP experiments (Figure 6A), 
which mandatorily require cell lysis.
To further detail the presence of mixed disulfides in the 
extracellular TF domain, sTF was subjected to liquid chroma-
tography–tandem mass spectrometry (LC-MS/MS). While sTF 
showed some heterogeneity, the major peak of the protein had a 
mass consistent with a single glutathionylation event. This peak 
represented 50%–60% of all detectable peaks. Single digestion of 
sTF with trypsin, GluC, or AspN yielded only poor sequence cov-
erage. However, after double digestion with trypsin, tryptic and 
semitryptic peptides were obtained yielding a sequence cover-
age of 68% (Supplemental Table 1; supplemental material avail-
able online with this article; doi:10.1172/JCI32376DS1). For the 
C49- and C57-containing peptides, the experimentally obtained 
masses were about 2 Da lower than the calculated masses (based 
on the assumption that both cysteines were reduced). This is con-
sistent with a loss of 2 H atoms due to disulfide bond formation 
between the N-terminal cysteines. All peptides containing C209 
were found with a 305.1-Da mass shift to their predicted masses, 
consistent with glutathionylation of C209. This does not exclude 
the presence of other thiol modifications at C209 that might have 
escaped detection, such as other types of mixed disulfides and/or 
intramolecular disulfides between C186 and C209. To definitely 
clarify the structure of the C209-containing peptides, they were 
subjected to MS/MS fragmentation. As shown for the peptide 
202-214 (Figure 6B), this induces cleavage of the peptide bonds 
between the individual amino acids of this peptide and thus gen-
erates peptide fragments of all possible chain lengths. The differ-
ences in masses between the C209-containing peptide fragments 
b7 and b8 and between the C209-containing fragments y6 and y5 
yielded values of 305.07. This corresponds to the mass difference 
between reduced cysteine (103.01) and glutathionylated cysteine 
(408.08) and thus establishes the presence of glutathione at C209. 
Similar results were obtained when the peptides 202-210 and 202-
212 were fragmented. Thus C209 in sTF is constitutively conju-
gated with glutathione.
To analyze the effect of glutathionylation on TF procoagulant 
activity, monocyte TF was first activated by cell lysis, and then 
DTT (0.1 mM) was added to reduce part of the redox-active cys-
teines of TF. This DTT concentration was chosen because higher 
DTT concentrations by themselves completely inhibited TF activ-
ity of the cell lysates (Figure 6C; see below). Subsequently, reduced 
glutathione (GSH) was added in the presence of diamide to convert 
the reduced cysteines into mixed disulfides with glutathione (see 
legend to Figure 6C). As a consequence of experimental TF gluta-
thionylation, the TF activity was decreased (Figure 6C). Control 
experiments were performed with GSH alone or DTT plus GSH. 
This did not alter TF activity. In the presence of higher DTT con-
centrations (1 mM) alone, which were verified not to alter TF fold-
ing (see Methods), TF activation by cell lysis was almost completely 
blocked (Figure 6C). This suggests that TF activation by cell lysis 
occurs via a redox-dependent mechanism. The results moreover 
indicate that glutathionylation contributes to TF encryption.
PDI converts TF cysteines from glutathionylated to disulfide state. PDI 
has 2 redox-active CXXC sites, which can exist in dithiol or disul-
fide states and which determine the type of redox reactions PDI 
can catalyze. The predominant redox state of PDI in vivo is the 
reduced dithiol form (29). Similarly, we found that the majority of 
the redox-active cysteines of the recombinant PDI used here were 
in the reduced state (see Methods). Since PDI is capable of cata-
lyzing deglutathionylation reactions (30), we tested the effect of 
isolated PDI on TF glutathionylation. sTF was labeled with biotin-
glutathione (Figure 7A). In control experiments we verified that the 
linkage of labeled glutathione with TF could be disrupted by DTT 
and GRX (Figure 7A), in line with their ability to deglutathionyl-
ate proteins (28). PDI partially deglutathionylated TF (Figure 7B). 
The ability to cleave the glutathione linkage of sTF was slightly 
enhanced when the redox-active cysteines of PDI were completely 
reduced with DTT (PDIred). By contrast, after complete oxidation 
of these cysteines (PDIox) with oxidized glutathione (GSSG), PDIox 
did not alter TF glutathionylation, indicating that PDI needs to be 
in the reduced state to cleave the glutathione linkage.
Figure 5
PDI decreases TF free thiols. (A) PDI lowers TF free thiols. Top panels: 
sTF (1.7 μg/ml) was exposed for 15 minutes to platelet releasates from 
collagen-activated platelets (5 × 108), TRX (10 μM), or PDI (1.8 μM). 
In all cases, sTF was then incubated with biotin-MPB. One aliquot was 
then pulled down with streptavidin agarose, and subsequently the bioti-
nylated proteins were detected by immunoblotting with anti-TF antibody 
(MPB-IB). Another aliquot of the sTF previously incubated with MPB 
was directly subjected to western blotting. Bottom panels: Densitomet-
ric analyses of the effects of TRX and PDI on sTF free thiols. *P < 0.05. 
n = 4. (B) PDI causes disulfide formation of cell TF. TF expressing 
monocytes (106) were incubated for 15 minutes with PDI or vehicle. The 
cells were subsequently washed and then incubated with biotin-MPB. 
The biotinylated proteins were selected with streptavidin-agarose. Bio-
tinylated TF species were detected by immunoblotting with anti-TF anti-
body. Western blots were performed under identical conditions.
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To evaluate the consequences of the deglutathionylation for the 
free thiol status of TF, we determined MPB labeling of sTF in the 
presence of different PDI species. PDI and PDIred, but not PDIox, 
decreased the free thiol content of sTF (Figure 7C), consistent 
with the formation of intramolecular disulfides of TF. In contrast, 
GRX, which also deglutathionylates TF (Figure 7A), increased the 
TF free thiols (data not shown). This shows that PDIred does not 
deglutathionylate TF to the free thiol as does GRX. Instead, PDI 
in its reduced form is likely to catalyze an isomerization reaction 
from a free thiol and a glutathionylated thiol to the C186/C209 
disulfide (see Discussion).
Next we assessed the influence of PDI on the procoagulant 
activity of TF. Under basal conditions, monocyte TF was largely 
inactive. However, PDI markedly increased monocyte TF activity 
(Figure 8A). This effect was completely suppressed by the anti-TF 
antibody (Figure 8A). In contrast to PDI, GRX (from E. coli, in the 
presence of GSH to maintain GRX in the fully reduced state) and 
TRX, which both reduce the redox-active cysteines of TF, did not 
enhance TF activity (Figure 8A). PDI (1.8 μM, 15-minute incuba-
tion) also increased the procoagulant activity of sTF (25 nM), while 
TRX (10 μM) did not alter the activity of sTF (control: 100%, PDI: 
208% ± 9%, P < 0.05; TRX: 105% ± 38%; n = 4, 2-stage assay). To test 
Figure 6
Constitutive glutathionylation of TF. (A) Basal glutathionylation of cell TF. Solubilized monocytes were immunoprecipitated with anti-GSH anti-
body or with isotype control antibody, as described in Methods. This was followed by western blotting with control antibody or anti-TF antibody. 
(B) Structure of C209 containing peptide STDSPVEC*MGQEK as identified by MS/MS fragmentation. The spectrum was generated by collision-
induced dissociation (CID) of the doubly charged 858.33-m/z ion. CID of doubly charged precursor ions predominately forms singly charged 
product ions that are indicative of the sequence of a peptide. The product ions thus generated are b-ions from the N-terminal site and y-ions 
from the C-terminal site. Peptide fragments observed in the mass spectrometer are shown in bold. The mass difference between b7 and b6 ions 
shows that the cysteine contains a modification equal to a glutathionylation from the N-terminal site. This is confirmed by the same mass differ-
ence between the y5 and y6 ion from the C-terminal site. (C) Glutathionylation attenuates TF activation. Cell lysis increases procoagulant activity, 
relative to intact cells, which is completely inhibited by anti-TF antibody. Increasing concentrations of DTT suppress TF activity. Glutathionylation 
in lysed cells was induced by preincubation with DTT (0.1 mM), followed by incubation with GSH (0.1 mM plus 0.1 mM diamide; 15 minutes). 
This increased the density of the band representing glutathionylated TF in immunoblots of lysed monocytes by 5.5-fold. Procoagulant activity of 
the lysates was determined by coagulation factor concentrate. *P < 0.05 versus control. n = 3–9.
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whether the redox-active cysteine CXXC sites of PDI are required 
for TF activation, we used a PDI mutant in which all cysteines are 
replaced by serine (PDIΔCys1,2). This mutant lacks the oxidore-
ductase activity of PDI but retains its chaperone function (44). In 
contrast to native PDI, PDIΔCys1,2 did not enhance TF activity 
(Figure 8B). Furthermore, PDIΔCys1,2 did not share the ability of 
native PDI to deglutathionylate TF (Figure 8B). To reveal whether 
the thiol status of the redox-active cysteines of PDI is of relevance 
for its ability to activate TF, we tested the effects of PDIred and 
PDIox on the activity of cell TF. PDIred augmented TF activity to a 
comparable degree as underivatized PDI, while PDIox was consider-
ably less effective (Figure 8B). Hence activation of TF requires the 
presence of the redox-active cysteines of PDI and is most efficient 
when these cysteines are in the reduced form. Together, our results 
suggest that PDI can activate TF by an 
isomerization reaction, which proceeds 
via mixed disulfide cleavage and subse-
quent disulfide bond formation.
Discussion
Our study suggests that exposure of the 
oxidoreductase PDI at vessel lesions con-
tributes to stimulate the crucial first step 
of blood coagulation, activation of the 
trigger protein TF. This indicates that 
disulfide isomerases may be major initia-
tors of fibrin formation, which can con-
vert TF from the functionally silent (or 
encrypted) state to the active form (Fig-
ure 9). In addition to other mechanisms, 
such as exposure of phosphatidylserine 
(10), PDI can indeed directly promote TF-
dependent fibrin formation. We identify 
constitutive linkages of TF Cys209 with 
glutathione that maintain TF in a status 
of low procoagulant functionality. The 
redox-active cysteines of intracellular and 
cell-released PDI are predominantly pres-
ent as free thiols (29, 31). Moreover, we 
found that TF is more efficiently activat-
ed by reduced PDI than by oxidized PDI. 
Since PDI decreases the free thiols of TF, 
it activates TF by a specific type of disul-
fide exchange that allows the reduced 
enzyme to induce the formation of intra-
molecular disulfides in TF. This suggests 
that PDI can initiate blood coagulation 
through isomerization of the Cys186/
Cys209 pair of TF (Figure 9).
This could potentially proceed via 
the generation of an unstable mixed 
disulfide between the N-terminal active 
site cysteine of PDI and Cys209 of TF, 
followed by a nucleophilic attack by 
Cys186 on this intermolecular disul-
fide. The alternative product of the first 
step, the formation of a PDI-GSH mixed 
disulfide, is not favored (30). Apart from 
the glutathionylated forms, the TF cys-
teines might assume additional redox 
states. Overall, mixed disulfides are apparently critical for the TF 
activation via reduced PDI, as they provide the redox equivalents 
required for generation of the Cys186/Cys209 disulfide. Since an 
increasing number of proteins are characterized as substrates for 
glutathionylation (28) and PDI can regulate the functionality of 
several proteins via fast redox switching (such as, for example, 
platelet surface receptors and MHC class I molecules; refs. 17, 32), 
the type of disulfide switch promoted by PDI as identified here is 
likely to be of general relevance. Moreover, the findings suggest for 
the first time a major relevance for the posttranslational mecha-
nism of disulfide switching under in vivo conditions.
The nature of the TF activation mechanism described implies 
that the redox status of the thiol isomerase itself remains unal-
tered after its interaction with TF. Consequently relatively few 
Figure 7
Deglutathionylation and TF disulfide bond formation by reduced PDI. (A) Incorporation of 
glutathione into sTF is reverted by GRX and DTT. sTF (1.7 μg/ml) incorporates biotin-labeled 
glutathione (0.1 mM, in the presence of 0.1 mM diamide; 15 minutes). Where indicated, DTT 
(1 mM) and GRX (4 μM; in the presence of 1 mM GSH) were added together with biotin-labeled 
glutathione. The biotinylated proteins were captured by streptavidin-agarose and immunoblotted 
with anti-TF antibody (GSH-IB). In parallel, sTF was analyzed by western blotting. (B) Degluta-
thionylation of TF by PDI. Left: sTF was labeled with biotin-labeled glutathione in the absence 
(control) or presence of native PDI, fully oxidized PDI (PDIox), or fully reduced PDI (PDIred; all at 
1.8 μM, 15 minutes). Biotinylated proteins selected by streptavidin-agarose were immunoblotted 
with anti-TF antibody, and in parallel, sTF was analyzed by western blotting. Right: Quantification 
of labeling of sTF with biotin-glutathione by densitometry. *P < 0.05 (versus control). n = 4. (C) 
Reduced forms of PDI promote disulfide bond formation of TF. Left: sTF was exposed to vehicle 
(control) and native PDI, PDIox, or PDIred (all at 1.8 μM, 15 minutes, room temperature). Then, the 
samples were incubated with biotin-MPB. The biotinylated proteins were selected with strepta-
vidin-agarose, followed by detection of biotinylated sTF species by immunoblotting with anti-TF 
antibody. In parallel, western blots were performed. Right: Quantification of free thiols of sTF by 
densitometry. *P < 0.05 versus control.
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PDI molecules can in principle activate a substantial number of 
TF molecules. This will enable amplification of the vessel injury 
signal, which is required to promote rapid and optimal resealing 
of the vessel wound. Among the different redox modifications of 
TF so far identified, the Cys186/Cys209 intramolecular disulfide 
state is associated with TF activation. Our findings indicating that 
PDI activates TF via its oxidoreductase activity (see above) do not 
exclude the possibility that the enzyme might stimulate TF activity 
through additional mechanisms (33) or that under certain condi-
tions it might decrease TF activity via S-nitrosylation–dependent 
mechanisms (12). In intact cells, PDI is mostly expressed in the 
ER (20, 21, 34). After vascular injury, PDI is abundantly exposed 
on the luminal surface of the wounded vessel wall. The exposure 
is injury specific, since no PDI is detected on the surface of the 
intact vessel wall. The PDI released originates from adherent plate-
lets and, additionally, from disrupted vessel wall cells, since PDI 
release at the vessel injury site is also seen in thrombocytopenic 
mice. PDI released from both sources is proposed to act in concert 
to initiate coagulation (Figure 9). Future work will be required to 
exactly dissect the role of the different sources of PDI released at 
the injury site that trigger TF-dependent fibrin formation and the 
participation of PDI-mediated amplification of platelet activation. 
Nonetheless, since PDI is exposed at the vessel lesion in thrombo-
cytopenic mice, PDI inhibition decreases fibrin generation in mice 
with suppressed platelet adhesion, and since PDI stimulates the 
TF activity in isolated cells and microparticles, our findings sug-
gest that under the experimental conditions applied the oxidore-
ductase directly activates TF in vivo and in vitro.
Disulfide exchange reactions have been described for a num-
ber of proteins in cellular systems (35–38). Our study indicates a 
major relevance for disulfide switching in the regulation of vessel 
resealing. Several central aspects of the molecular machinery acti-
vating TF in vitro can indeed be recaptured in the intact organ-
ism, including the mediator function of PDI and the participa-
tion of TF thiol-disulfide exchange. We document activation of 
TF-dependent blood coagulation via PDI by intravital monitoring 
of the dynamics of fibrin formation at the site of vessel injury. PDI 
is found to promote fibrin generation both during the early phase 
of thrombus development (10–15 minutes post injury) and at later 
stages, when fibrin generation is also driven by microparticle TF, 
a circulating carrier for TF (9) that is selectively recruited to the 
growing thrombus (14, 15). In particular, the activity of micropar-
ticle TF is shown to be uncovered by platelet-secreted PDI.
Spontaneous rupture of endothelial cells covering atherosclerotic 
plaques initiates arterial thrombosis in humans in which blood 
coagulation is aberrantly activated (39, 40). Plaque rupture and con-
secutive thrombosis represent key mechanisms in the pathogenesis 
of cardiovascular diseases such as myocardial infarction and stroke. 
In the thrombosis models utilized in the present study, local fibrin 
generation is equally induced by disruption of the endothelial sur-
face, whereby substantial platelet accumulation is triggered. Conse-
quently, disulfide isomerases could potentially also trigger the coag-
ulation start during pathologic fibrin formation. They could thus 
represent novel targets for the treatment of thrombotic disorders. 
The anticoagulant action provided by PDI inhibition is expected to 
preferentially target the enzyme that is exposed at the lesion area. 
Since inhibition of PDI decreases fibrin formation also under condi-
tions of diminished platelet adhesion, therapeutic interventions are 
potentially suitable for an extended range of thrombotic diseases 
with varying participations of platelets. Nonetheless, additional 
studies are required to determine the effect of PDI inhibition in fur-
ther thrombosis models and on hemostasis.
Methods
Cells and microparticles. Human platelets and human monocytes were isolated 
as detailed earlier (9). Monocyte TF expression was induced by a 4-hour 
stimulation with 10 ng/ml LPS at 37°C. To generate microparticles in 
vitro, the isolated monocytes (3 × 106; suspended in RPMI) were activated 
by LPS (14 hours; 10 μg/ml LPS). The microparticles were prepared from 
the cell-free supernatants by centrifugation at 2,260 g (20 minutes), fol-
lowed by a second centrifugation at 17,750 g (30 minutes). The micropar-
ticles were suspended in resuspension buffer (138 mM NaCl, 2.7 mM KCl, 
12 mM NaHCO3, 0.4 mM NaH2PO4, 1 mM MgCl2, 5 mM glucose, 5 mM 
HEPES; pH 7.35). Only freshly prepared microparticle suspensions were 
Figure 8
TF activation requires reduced PDI. (A) TF activation by 
PDI. TF-expressing monocytes were incubated with native 
PDI (1.8 μM), TRX (10 μM), or GRX (4 μM; in the presence 
of 1 mM GSH) for 15 minutes at room temperature. Then, 
the procoagulant activity was determined by 2-stage assay. 
Apart from anti-TF antibody (10 μg/ml), pretreatment of 
monocytes with the free thiol–selective reagent DTNB 
also inhibited stimulation of TF activity by PDI (data not 
shown). *P < 0.05 (versus control); n = 4. (B) Relevance 
of redox-active cysteines for TF activation by PDI. Bottom: 
TF-expressing monocytes were incubated with native PDI 
and a PDI mutant in which the redox-active cysteines were 
substituted by serine (PDIΔCys1,2). Additionally, the cells 
were incubated with PDIred and PDIox (all at 1.8 μM). Then, 
the procoagulant activity was determined (2-stage assay). 
n = 4. Top: In contrast to native PDI, PDIΔCys1,2 did not 
deglutathionylate sTF. *P < 0.05 versus control; #P < 0.05 
versus native PDI.
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used, and the time period until their injection into mice (in 250-μl por-
tions) was less than 2 hours. Microparticle numbers were assessed by mea-
suring the volume of microparticle suspensions corresponding to 10,000 
events with a diameter between 0.1 and 0.8 μm (9).
TF and PDI variants. sTF 1-214 was expressed in E. coli and purified under 
the same conditions as previously described (41). sTF was analyzed by 
circular dichroism using CDNN software for spectra deconvolution (42). 
The circular dichroism spectrum of sTF thus obtained closely resembled 
the spectra previously obtained for sTF (43). The contents of secondary 
structure elements after deconvolution of the spectrum (spectral region 
200–260 nm: 7.6% [α-helical], 28.7% [antiparallel β-sheet], 4.5% [parallel 
β-sheet], 28.2% [β-turn], and 39.0% [random coil]) were similar to those 
deduced from the x-ray structure of TF and to previously published work 
(43). DTT (1 mM) did not modify the secondary structure of sTF. sTF 
(0.7 μg/ml) supported low TF activity (0.01 μM of factor Xa generation; 
2-stage assay). sTF was found to contain 0.98 mol of free thiols/mol sTF as 
measured by DTNB at 412 nm in Na-phosphate (80 mM, pH 7.1; extinc-
tion coefficient 38,390 M–1 cm–1; Ellman’s assay). Given that the N-termi-
nal cysteines are present as intramolecular disulfide (see below), this indi-
cated that 49% of the membrane-proximal cysteine pair of sTF was in the 
reduced form. MPB (0.1 mM; Molecular Probes) decreased the free thiols 
of sTF by 80%. Other work indicates that sTF 1-218 is largely devoid of free 
thiols (26, 33). We assume that the differences between those results and 
our findings are due to the shorter length of sTF used in the present study 
and/or due to subtle differences in the conditions used to prepare sTF. 
Mature human PDI was expressed in E. coli and subsequently isolated (44). 
Seventy to eighty percent of the redox active cysteines of native PDI were in 
the reduced form (extinction coefficient 14,150 M–1 cm–1). In parallel with 
native PDI, the mutant with Cys to Ser substitutions in the CGHC motifs 
of the a and a′ domains was isolated (PDIΔC1,2) (44).
TF-associated free thiols. sTF and cells were incubated under varying condi-
tions before labeling of free thiols with MPB. To assess the effect of plate-
let releasates on TF, platelets were activated with collagen (8 μg/ml) for 30 
minutes and the supernatant was recovered and freed from microparticles 
by centrifugation. The releasate was incubated for 15 minutes with sTF. 
Then the samples were treated for 30 minutes with MPB (0.1 mM), and 
the reaction was terminated by the addition of GSH (0.2 mM; 30 min-
utes). Labeled cells were washed 3 times with PBS containing protease 
inhibitor and phosphatase inhibitor cocktails (Roche). Then the samples 
were sonicated in ice-cold lysis buffer (50 mM Tris, 0.15 M NaCl; pH 8.0; 
also containing 1% Triton X-100 and 5 mM EDTA). Streptavidin-agarose 
beads (Sigma-Aldrich) were incubated with sTF or cell lysates overnight 
on a rotating wheel to isolate the biotin-labeled proteins. The streptavi-
din-agarose beads were washed 3 times with lysis buffer, and the biotin-
labeled proteins were released from the beads by boiling in SDS sample 
buffer (Laemmli buffer) for 3 minutes under nonreducing conditions. 
Samples were resolved on SDS-PAGE (7.5% and 16.5%) under nonreduc-
ing conditions and transferred to nitrocellulose membrane (Amersham 
Biosciences). After electroblotting, the membranes were exposed to the 
monoclonal anti-hTF antibody (VIC12; ref. 45) and a horseradish peroxi-
dase–conjugated anti-mouse IgG. The experiments shown are representa-
tive of a total of 3–4 experiments.
Immunoprecipitation. For the detection of the constitutive glutathionyl-
ation of TF, solubilized monocytes were centrifuged 3 times at 3,000 g for 
2 minutes at 4°C, and the supernatant was incubated with the monoclonal 
anti-GSH antibody (Virogen; or control IgG) overnight at 4°C. In other 
experiments, intact monocytes were incubated with anti-GSH antibody 
for 60 minutes at room temperature. Then, protein A Sepharose (Sigma-
Aldrich; 50 μl) was added and the mixture incubated for 60 minutes at 4°C. 
Immunoprecipitated complexes were collected by centrifugation at 3,000 g 
for 2 minutes at 4°C. After washing 3 times with PBS, the pellets were incu-
bated in SDS sample buffer (without reducing reagents) for 60 minutes at 
20°C. After centrifugation, the supernatant was subjected to SDS-PAGE 
(7.5%), followed by electroblotting onto the nitrocellulose membrane. The 
Figure 9
Model for the activation of TF-dependent coagulation start by 
PDI. Top: PDI exposure at the vessel injury site contributes to 
enable the initial step of the extrinsic pathway of blood coagula-
tion, conversion of TF from the functionally inactive to the active 
form. After vessel injury, PDI can be secreted by activated 
platelets (P) adhering at the injury site and released from cells 
of the damaged vessel wall. The exposed PDI might interact 
with TF expressed by vessel wall cells and TF carrying blood 
components such as microparticles rapidly recruited to the ves-
sel lesion. In parallel, the exposed PDI can directly contribute 
to amplify platelet activation. Bottom: Hypothetical molecular 
mechanism of TF activation by PDI. TF-dependent fibrin forma-
tion is low when the Cys186/Cys209 pair of TF is glutathionylat-
ed and/or in the free thiol form. Mixed disulfides with glutathione 
(and other types of linkages) at Cys209 are a constitutive redox 
form of the protein. PDI can cleave the mixed disulfides of TF 
when its redox-active cysteines are in the reduced form. This 
could potentially result in the formation of an unstable PDI-TF 
intermediate. Through nucleophilic attack by the vicinal free 
thiol, the intermediate might be disintegrated and be converted 
into a stable disulfide. The isomerization reaction proposed is 
thus in principle similar to the PDI-catalyzed isomerization sug-
gested to mediate the correct positioning of protein disulfides 
in the ER (21). After completing the redox exchange, the same 
PDI molecule can potentially stimulate additional TF molecules, 
which would amplify TF activation.
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membranes were then exposed to a monoclonal anti-TF antibody (or con-
trol IgG), followed by a horseradish peroxidase–conjugated anti-mouse 
IgG. The experiments were repeated 3 times.
TF glutathionylation. For the labeling of GSH with biotin, equimolar 
amounts (10 mM) of NHS-biotin (Pierce Biotechnology) and GSH dis-
solved in PBS were incubated at room temperature. The reaction was termi-
nated after 1 hour, the residual biotin being quenched with ethanolamine 
(50 mM). To enable the protein incorporation of the labeled glutathione, 
the cells (or sTF) were incubated for 30–60 minutes with biotin-GSH 
(5 mM). Subsequently, the cells were washed and solubilized with 1% Tri-
ton X-100 in PBS. sTF was dialyzed using centricon filters. Then streptavi-
din beads (Sigma) were added to the biotinylated proteins of the cells (or 
sTF) and the mixture was incubated overnight. After sedimentation of the 
beads, they were washed twice with PBS containing 0.2% Triton X-100. The 
proteins were eluted in SDS sample buffer, separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes, and the monoclonal anti-TF antibody 
was employed to detect the glutathionylated protein.
Mass spectrometry. A 20-μl aliquot of sTF (0.13 mg/ml) was digested with 
1 μg trypsin overnight. For double digests, the protein digestion mixture 
was spiked with another 1 μg trypsin for another 24 hours. Generated pep-
tides were subjected to LC-MS/MS analysis using LTQFT (Thermo Finni-
gan) or QTOF (Waters) mass spectrometry. The LTQFT hybrid mass spec-
trometer system consisted of a Waters CapLC and an LTQFT. Data were 
acquired in data-dependent mode with XCalibur 2.0 and processed with 
BioWorks. After digestion, the peptides were concentrated on a Waters 
Symmetry C18 trap column and, after a 5 minute delay, were directed 
onto a Vydac C18 column VC-10-18W-150 (10 cm × 150 μm i.d., 5 μm, 
300 Å pore size; MicroTech Scientific) for separation. Solvent A was 0.2% 
formic acid in water and solvent B was 0.2% formic acid in acetonitrile. 
The separation was started for the first 5 minutes with 95% solvent A, then 
a gradient was ramped from 5% to 35% B within 10 minutes. Solvent B 
was then ramped up to 90% over 10 minutes and held at 90% for 10 min-
utes. Then the starting conditions were restored to equilibrate the column. 
The flow was 6 μl/min in a split ratio of 1:10. Columns were kept at room 
temperature. The QTOF2 hybrid mass spectrometer system consisted of a 
nanoAcquity UPLC and a QTOF2. Data were acquired in a data-dependent 
mode and processed with MassLynx 4.0 using a similar setup as described 
above. The peptide fragment data obtained from the LTQFT were pro-
cessed using BioWorks to create data files that were merged using a PERL 
program (provided by MatrixScience and modified in our laboratory) for 
subsequent database searches. QTOF data were processed accordingly 
using MassLynx. A Mascot search engine was used for database searches, 
applying the following parameters: SwissProt database, charge states +2 
and +3, 1 missed cleavage. A window of 5 ppm mass accuracy for precur-
sor ions and 0.6 Da accuracy for MS/MS data was chosen for the LTQFT 
data. For QTOF data, a window of 0.3 Da mass accuracy for precursor ions 
and for MS/MS data was chosen. Probability-based MASCOT scores were 
considered significant when greater than the cutoff score, indicating either 
identity or homology (P < 0.05) for individual ions.
Procoagulant activity. TF-expressing cells, platelets and microparticles 
were incubated for different time intervals. To neutralize the TF activ-
ity of monocyte microparticles, a monoclonal anti-hTF antibody (VIC7; 
ref. 46) was used. To assess whether microparticle TF was responsible for 
the TF activity in suspensions of activated platelets and microparticles, iso-
lated microparticles and activated platelets (10-minute stimulation with 
collagen type I, 8 μg/ml) were separately incubated with anti-TF antibody 
(VIC7). Then, microparticles and platelets were centrifuged (at 17,750 g 
and 330 g, respectively), the supernatants were removed to eliminate free 
antibody, and the blood components were suspended in resuspension buf-
fer. In separate samples, bacitracin (6 mM; Sigma-Aldrich), and anti-PDI 
(mab3-019; or isotype control antibody, both diluted 1:70; Affinity Bio-
reagents) were added. To prepare cell lysates, human monocytes (for the 
experiments shown in Figure 6C) or CHO cells were suspended in 30 μl 
of PBS containing 15 mM of octyl-β-d-glucopyranoside (Sigma-Aldrich), 
frozen at –80°C for 15 minutes, and thawed. TF activity was determined 
using a 2-stage assay in the presence of FVIIa (2 nM; Novo Nordisk) and 
CaCl2 (25 mM) for 15 minutes at room temperature, followed by addition 
of FX (200 nM; Calbiochem) for a further 30 minutes at room temperature. 
When CaCl2 concentrations were reduced to 8 mM, TF activity was stimu-
lated by PDI in a way comparable to that used at higher CaCl2 concentra-
tions. TF activity was also measured using a coagulation factor concentrate 
as previously described (9). S2222 was employed to assess the amount of 
factor Xa generated. The method employs a synthetic substrate specific 
for factor Xa, the product of hydrolysis being directly proportional to the 
amount of factor Xa present.
Animals. WT mice (SV129S1) were obtained from Charles River. Low-hTF 
mice and mice harboring hTF (both on a C57BL/6 background) were gener-
ated as previously described (23, 24). The mice used were age matched and 
did not differ in carotid arterial diameter and thickness of the vessel wall.
In vivo model of intravascular coagulation by carotid artery ligation. For injury 
of the carotid artery (18), mice were anesthetized by intraperitoneal injec-
tion of a solution of midazolame (5 mg/kg body weight; Ratiopharm), 
medetomidine (0.5 mg/kg body weight; Pfizer), and fentanyl (0.05 mg/kg 
body weight; CuraMed Pharma). The common carotid artery was dis-
sected free, and endothelial denudation was induced near the carotid 
bifurcation by ligation of the vessel until complete cessation of the blood 
flow occurred. The ligation was removed after 5 minutes. All procedures 
performed on mice were approved by the local legislation on protection of 
animals (Regierung von Oberbayern, Munich, Germany). Fibrin formation 
was visualized by high-speed intravital microscopy by a modification of a 
previous published technique (47). To detect fibrin in vivo, a monoclonal 
antibody against the fibrin IIβ chain (Bβ 15-42, Clone T2G1; Accurate 
Chemical) was labeled with Alexa Fluor 488 using the Alexa Fluor Protein 
Labeling Kit (Molecular Probes) according to the manufacturer’s instruc-
tions and infused intravenously (2 mg/kg body weight). Isotype-matched 
irrelevant IgG (mouse IgG2a; Sigma-Aldrich) was used as a negative con-
trol. Fibrin formation is presented as absolute fluorescence intensity (arbi-
trary units). To evaluate the contribution of the microparticles for fibrin 
formation in vivo, monocyte microparticles (107, suspended in 250 μl) 
were infused into the jugular vein. The residual amounts of LPS present 
in the preparations of washed microparticles alone do not account for the 
rapid increase in fibrin formation after microparticle infusion. In some 
experiments, mice were treated with anti-PDI and control antibody (800 
μg/animal; mab3-019 or respective control antibody; Affinity Bioreagents) 
or with PDI (200 μg/animal). Endothelial disruption was induced, trigger-
ing local platelet adhesion and aggregation. In parallel experiments, the 
microparticles were labeled with 5-carboxyfluorescein diacetate succin-
imidyl ester (DCF) before inclusion into the blood circulation of mice 
pretreated with the anti-PDI antibody (or control IgG). Local micropar-
ticle accumulation was determined by intravital microscopy. Where indi-
cated, platelets were differentially tagged with rhodamine 6G and infused 
together with the labeled microparticles to directly assess the interaction 
between the 2 blood components. In separate experiments, the require-
ment of platelets for the PDI-evoked fibrin formation was evaluated. 
Mice were pretreated with 6 mg/kg of monoclonal rat anti-mouse GPVI 
antibody (IgG2a, clone IF5-1-11; kindly provided by Elisabeth Kremmer, 
GSF Research Center of Environment and Health, Munich, Germany). 
The specificity of the antibody was verified by its ability to recognize a 
single band at the expected molecular weight of GPVI in murine platelets. 
Alternatively, a mixture of anti-GPIbα antibodies (50 μg/mouse, R300; 
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Emfret Analytics) was infused into mice to decrease platelet adhesion via 
induction of thrombocytopenia (22). Fibrin formation was subsequently 
determined in the presence of the anti-PDI antibody (or control IgG) by 
intravital microscopy. For detection of PDI in vivo by intravital micros-
copy, an Alexa Fluor 488–labeled anti-PDI antibody (H-160; Santa Cruz 
Biotechnology Inc.) or control IgG was injected into the murine blood 
circulation (20 μg/mouse).
Activation of in vivo coagulation by wire-induced vascular injury. Wire-induced 
endothelial disruption was performed as previously described (18).
Tail bleeding. Tails of WT mice were cut 5 mm from the tip with a scalpel, 
and the time was measured until bleeding stopped using a paper filter.
Detection of fibrin ex vivo. Thirty minutes after induction of carotid injury, 
the arteries were excised, gently flushed with PBS to remove residual blood, 
and immediately frozen using liquid nitrogen. Segments (2 mm) of injured 
vessels or control vessels were homogenized and lysed in a buffer contain-
ing protease inhibitors. Proteins were separated on SDS-PAGE (4%–20%) 
and transferred to nitrocellulose membranes. This was followed by incu-
bation with mouse anti-fibrin II β chain antibody (Bβ 15-42, clone T2G1; 
Accurate Chemical; 2 μg/ml) and treatment with horse radish peroxidase–
tagged anti-mouse IgG H+L (Vector, 0.5 μg/ml). Finally, the membranes 
were developed by chemiluminescence (PerkinElmer).
Intravital imaging. We used a high-speed widefield Olympus BX51WI 
fluorescence microscope with a long-distance condenser and a ×20 (NA 
0.95) water-immersion objective for intravital imaging of fibrin forma-
tion, platelet adhesion and microparticle recruitment. The digital micro-
scope allows near-simultaneous collection of images in 3 separate chan-
nels, each monitoring a different fluorescence emission. The system is 
equipped with an Olympus MT 20 monochromator for excitation and 
a F-View CCD camera (Olympus). A Dell workstation with the Olympus 
Cell/R software was used for synchronization of components, data acqui-
sition, and image analysis.
Immunohistochemistry. Fifteen minutes following ligation of the murine 
carotid artery, injured vessel sections were excised. Sections of the vessels 
were exposed to Alexa Fluor 594–labeled rat anti-CD41 antibody (BD Bio-
sciences) and to Alexa Fluor 488–labeled anti-PDI antibody (H-160; Santa 
Cruz Biotechnology Inc.).
Statistics. All data shown represent means ± SD, unless otherwise indicated. 
Measurements performed under identical conditions and time points were 
analyzed by Mann-Whitney rank sum test. Consecutive measurements 
were compared by ANOVA repeated measurements. P < 0.05 was consid-
ered statistically significant.
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